NCT03806764View on ClinicalTrials.gov

Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient

NAUnknownINTERVENTIONAL
Enrollment

370

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Cytomegalovirus InfectionsHaematological MalignancyOrgan or Tissue Transplant; ComplicationsImmune Suppression
Interventions
DIAGNOSTIC_TEST

Blood sampling

Blood sampling from prospective study participants will be taken for immune functions measurements

Trial Locations (1)

3050

Royal Melbourne Hospital, Parkville

Sponsors

Lead Sponsor

Melbourne Health
All Listed Sponsors
collaborator

Peter MacCallum Cancer Centre, Australia

OTHER

collaborator

Western Sydney Local Health District

OTHER

collaborator

Walter and Eliza Hall Institute of Medical Research

OTHER

collaborator

Austin Hospital, Melbourne Australia

OTHER

lead

Melbourne Health

OTHER

NCT03806764 - Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient | Biotech Hunter | Biotech Hunter